Inhibikase Therapeutics Ownership 2024 | Who Owns Inhibikase Therapeutics Now?

Overview RevenueFinancials Chart Transcripts

Institutional Ownership

0.05%

Insider Ownership

12.02%

Retail Ownership

87.93%

Institutional Holders

1.00

Inhibikase Therapeutics Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
HAMILTON LANE ADVISORS LLC	-	-	-	-13,802	-100.00%	-	Sep 30, 2023

Inhibikase Therapeutics's largest institutional shareholder is HAMILTON LANE ADVISORS LLC, holding 0.00% of the company's total share outstanding, currently valued at -. The top 10 institutional shareholders own together 0.00% of the company.

Institutional Shareholders by % of Total Assets

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
HAMILTON LANE ADVISORS LLC	-	-	-	-13,802	-100.00%	-	Sep 30, 2023

The largest Inhibikase Therapeutics shareholder by % of total assets is HAMILTON LANE ADVISORS LLC. The company owns 0.00 shares of Inhibikase Therapeutics (IKT), representing 0.00% of its total assets.

Institutional Buyers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
HAMILTON LANE ADVISORS LLC	-	-	-	-13,802	-100.00%	-	Sep 30, 2023

As of Sep 30 2023, Inhibikase Therapeutics's largest institutional buyer is HAMILTON LANE ADVISORS LLC. The company purchased -13.80K stocks of IKT, valued at -.

Institutional Sellers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
HAMILTON LANE ADVISORS LLC	-	-	-	-13,802	-100.00%	-	Sep 30, 2023

As of Sep 30 2023, Inhibikase Therapeutics's biggest institutional seller is HAMILTON LANE ADVISORS LLC. The company sold -13.80K shares of IKT, valued at -.

Institutional New positions

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date

Institutional Sold Out

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
HAMILTON LANE ADVISORS LLC	-	-	-	-13,802	-100.00%	-	Sep 30, 2023

Inhibikase Therapeutics's largest sold out institutional shareholder by shares sold is HAMILTON LANE ADVISORS LLC, sold -13.80K shares, valued at -, as of undefined.

Inhibikase Therapeutics Mutual Fund Holders

Name	% Total Assets	Total Shares	Change Amount	Change %	Date
360 Funds	0.16%	33,000	-	-	Feb 29, 2024
360 Funds	0.05%	11,000	5,500	100.00%	Mar 31, 2024
VANGUARD VALLEY FORGE FUNDS	0.02%	11,895	-	-	Mar 31, 2024
FIDELITY SELECT PORTFOLIOS	0.01%	433,300	-	-	Feb 29, 2024
VANGUARD VALLEY FORGE FUNDS	0.00%	1,913	-	-	Mar 31, 2024
VANGUARD INDEX FUNDS	0.00%	510,292	-	-	Mar 31, 2024
FIDELITY CONCORD STREET TRUST	0.00%	81,120	-	-	Feb 29, 2024
FIDELITY CONCORD STREET TRUST	0.00%	27,688	-103	-0.37%	Feb 29, 2024
VANGUARD INDEX FUNDS	0.00%	16,724	-73,577	-81.48%	Mar 31, 2024
USAA MUTUAL FUNDS TRUST	0.00%	2,031	-	-	Jan 31, 2024
iSHARES TRUST	0.00%	48,089	-	-	Mar 31, 2024
EQ ADVISORS TRUST	0.00%	3,408	-	-	Mar 31, 2024

Inhibikase Therapeutics's largest mutual fund holder by % of total assets is "360 Funds", owning 33.00K shares, compromising 0.16% of its total assets.

Inhibikase Therapeutics Institutional Ownership Trends

Institutional Holdings Trend

Date	Holdings	Change %
30 Jun, 23	1	-94.12%
31 Mar, 23	17	-10.53%
31 Dec, 22	19	-13.64%
30 Sep, 22	22	10.00%
30 Jun, 22	20	-13.04%
31 Mar, 22	23	-
31 Dec, 21	23	15.00%
30 Sep, 21	20	53.85%
30 Jun, 21	13	62.50%
31 Mar, 21	8	60.00%
31 Dec, 20	5	-

As of 30 Jun 23, 1 institutions are holding Inhibikase Therapeutics's shares, representing a decrease of -94.12% compared to the previous quarter.

Shares Outstanding Trend

Date	Shares Outstanding	Change %
30 Jun, 23	13,802	-99.69%
31 Mar, 23	4,421,111	206.88%
31 Dec, 22	1,440,673	-52.69%
30 Sep, 22	3,045,355	-9.10%
30 Jun, 22	3,350,331	-21.64%
31 Mar, 22	4,275,402	-8.23%
31 Dec, 21	4,659,048	13.68%
30 Sep, 21	4,098,248	8.00%
30 Jun, 21	3,794,682	2233.62%
31 Mar, 21	162,609	20.41%
31 Dec, 20	135,050	-

Inhibikase Therapeutics (IKT) has 13.80K shares outstanding as of 30 Jun 23, down -99.69% compared to the previous quarter.

Institutional Ownership Trend

Date	Ownership %	Change %
30 Jun, 23	0.05%	0.02%
31 Mar, 23	16.07%	49.22%
31 Dec, 22	5.71%	3.92%
30 Sep, 22	12.07%	6.84%
30 Jun, 22	13.28%	4.62%
31 Mar, 22	16.96%	4.94%
31 Dec, 21	18.53%	6.97%
30 Sep, 21	16.30%	7.16%
30 Jun, 21	15.09%	3608.50%
31 Mar, 21	0.65%	224.19%
31 Dec, 20	0.54%	-

As of 30 Jun 23, Inhibikase Therapeutics is held by 0.05% institutional shareholders, representing a 0.02% growth compared to 31 Mar 23.

Institutional Increased Positions Trend

Date	Increased Positions	Change %
30 Jun, 23	-	-100.00%
31 Mar, 23	7	-22.22%
31 Dec, 22	9	80.00%
30 Sep, 22	5	-50.00%
30 Jun, 22	10	25.00%
31 Mar, 22	8	-33.33%
31 Dec, 21	12	-14.29%
30 Sep, 21	14	7.69%
30 Jun, 21	13	160.00%
31 Mar, 21	5	-
31 Dec, 20	5	-

- institutional shareholders have increased their position in IKT stock as of 30 Jun 23 compared to 7 in the previous quarter (a -100.00% decrease).

Institutional Reduced Positions Trend

Date	Reduced Positions	Change %
30 Jun, 23	1	-50.00%
31 Mar, 23	2	-60.00%
31 Dec, 22	5	25.00%
30 Sep, 22	4	-
30 Jun, 22	4	-33.33%
31 Mar, 22	6	100.00%
31 Dec, 21	3	200.00%
30 Sep, 21	1	-
30 Jun, 21	-	-100.00%
31 Mar, 21	1	-
31 Dec, 20	-	-

1 institutional shareholders have reduced their position in IKT stock as of 30 Jun 23 compared to 2 in the previous quarter (a -50.00% decrease).

All Institutional Ownership Trend Data

Date	Holdings	Change %	Shares Outstanding	Change %	Ownership %	Change %	Increased Positions	Change %	Reduced Positions	Change %
30 Jun, 23	1	-94.12%	13,802	-99.69%	0.05%	0.02%	-	-100.00%	1	-50.00%
31 Mar, 23	17	-10.53%	4,421,111	206.88%	16.07%	49.22%	7	-22.22%	2	-60.00%
31 Dec, 22	19	-13.64%	1,440,673	-52.69%	5.71%	3.92%	9	80.00%	5	25.00%
30 Sep, 22	22	10.00%	3,045,355	-9.10%	12.07%	6.84%	5	-50.00%	4	-
30 Jun, 22	20	-13.04%	3,350,331	-21.64%	13.28%	4.62%	10	25.00%	4	-33.33%
31 Mar, 22	23	-	4,275,402	-8.23%	16.96%	4.94%	8	-33.33%	6	100.00%
31 Dec, 21	23	15.00%	4,659,048	13.68%	18.53%	6.97%	12	-14.29%	3	200.00%
30 Sep, 21	20	53.85%	4,098,248	8.00%	16.30%	7.16%	14	7.69%	1	-
30 Jun, 21	13	62.50%	3,794,682	2233.62%	15.09%	3608.50%	13	160.00%	-	-100.00%
31 Mar, 21	8	60.00%	162,609	20.41%	0.65%	224.19%	5	-	1	-
31 Dec, 20	5	-	135,050	-	0.54%	-	5	-	-	-

Inhibikase Therapeutics Insider Shareholders Trades

Open Market Insider Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source
Aug 16, 2022	Werner Milton H.	officer	President and CEO	P-Purchase	Buy	5,000	$0.80	$4.00K	5,335,433

Open Market Insider Buys

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source
Aug 16, 2022	Werner Milton H.	officer	President and CEO	P-Purchase	Buy	5,000	$0.80	$4.00K	5,335,433

Insider Sells

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source
Apr 02, 2024	Lees-Rolfe Garth	officer	Chief Financial Officer		Sell	5,834	$3.79	$22.11K	-

All Insider Owners Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Jul 18, 2024	GRINT PAUL C	director	-	A-Award	Buy	30,000	$1.54	$46.20K	30,000
Jul 18, 2024	Dion Gisele	director	-	A-Award	Buy	30,000	$1.54	$46.20K	30,000
Jul 18, 2024	BERMAN DENNIS N	director	-	A-Award	Buy	30,000	$1.54	$46.20K	30,000
Jul 18, 2024	Freeman Roy Lester	director	-	A-Award	Buy	30,000	$1.54	$46.20K	30,000
Apr 03, 2024	Werner Milton H.	director, 10 percent owner, officer	President and CEO	A-Award	Buy	45,000	$2.16	$97.20K	45,000
Apr 02, 2024	Lees-Rolfe Garth	officer	Chief Financial Officer	A-Award	Buy	90,000	$2.16	$194.40K	90,000
Apr 02, 2024	Lees-Rolfe Garth	officer	Chief Financial Officer		Sell	5,834	$3.79	$22.11K	-
Jul 05, 2023	BERMAN DENNIS N	director	-	A-Award	Buy	6,667	$3.61	$24.07K	6,667
Jul 05, 2023	Dion Gisele	director	-	A-Award	Buy	6,667	$3.61	$24.07K	6,667
Jul 05, 2023	GRINT PAUL C	director	-	A-Award	Buy	6,667	$3.61	$24.07K	6,667
Jul 05, 2023	Freeman Roy Lester	director	-	A-Award	Buy	6,667	$3.61	$24.07K	6,667
Mar 03, 2023	Werner Milton H.	director, 10 percent owner, officer	President and CEO	A-Award	Buy	210,000	$0.74	$155.40K	210,000
Mar 03, 2023	FRATTAROLI JOSEPH	officer	Cheif Financial Officer	A-Award	Buy	90,000	$0.74	$66.60K	90,000
Sep 06, 2022	Dion Gisele	director		A-Award	Buy	60,000	-	-	60,000
Sep 06, 2022	Dion Gisele	director			Buy	-	-	-	-
Aug 16, 2022	Werner Milton H.	officer	President and CEO	P-Purchase	Buy	5,000	$0.80	$4.00K	5,335,433
Jun 28, 2022	Freeman Roy Lester	director		A-Award	Buy	40,000	-	-	40,000
Jun 28, 2022	Freeman Roy Lester	director	-	A-Award	Buy	40,000	$0.81	$32.40K	40,000
Jun 28, 2022	GRINT PAUL C	director		A-Award	Buy	40,000	-	-	40,000
Jun 28, 2022	GRINT PAUL C	director	-	A-Award	Buy	40,000	$0.81	$32.40K	40,000

The last insider sell of Inhibikase Therapeutics's stock was made by Lees-Rolfe Garth on Apr 02 2024, selling 5,834 shares at $3.79 per share (valued at $22.11K). The last insider buy of IKT was made by Werner Milton H. on Aug 16 2022, buying 5,000 shares at $0.80 per share (worth $4.00K).

Inhibikase Therapeutics Insider Ownership Trends

All Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q3 2024	4	-	-
Q2 2024	2	1	200.00%
Q2 2023	4	-	-
Q1 2023	2	-	-
Q3 2022	2	-	-
Q2 2022	10	-	-
Q1 2022	8	1	800.00%
Q4 2021	5	-	-
Q3 2021	1	1	100.00%
Q2 2021	5	2	250.00%
Q4 2020	7	9	77.78%
Q2 2011	-	2	-

4 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Inhibikase Therapeutics's insiders, as of Q3 2024.

Open Market Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q3 2024	-	-	-
Q2 2024	-	-	-
Q2 2023	-	-	-
Q1 2023	-	-	-
Q3 2022	1	-	-
Q2 2022	3	-	-
Q1 2022	-	-	-
Q4 2021	5	-	-
Q3 2021	-	-	-
Q2 2021	-	-	-
Q4 2020	-	-	-
Q2 2011	-	-	-

As of Q3 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Inhibikase Therapeutics's stocks.

Inhibikase Therapeutics Peer Ownership

Ticker	Company
SIOX	Sio Gene Therapies Inc.
PMVP	PMV Pharmaceuticals, Inc.
NTRB	Nutriband Inc.
SCPH	scPharmaceuticals Inc.
LGVN	Longeveron Inc.
QNRX	Quoin Pharmaceuticals, Ltd.
MCRB	Seres Therapeutics, Inc.
ANTX	AN2 Therapeutics, Inc.
VRAX	Virax Biolabs Group Limited
ONCY	Oncolytics Biotech Inc.
RNXT	RenovoRx, Inc.
DMAC	DiaMedica Therapeutics Inc.
TPST	Tempest Therapeutics, Inc.
ANEB	Anebulo Pharmaceuticals, Inc.
MIST	Milestone Pharmaceuticals Inc.
LIFE	aTyr Pharma, Inc.

IKT Ownership FAQ

Who Owns Inhibikase Therapeutics?

Inhibikase Therapeutics is owned by institutional shareholders (0.05%), insiders (12.02%), and public (87.93%). The largest institutional shareholder of Inhibikase Therapeutics is HAMILTON LANE ADVISORS LLC (0% of total shares) and the top mutual fund owner is 360 Funds (0.16% of total shares).

Who are the major institutional shareholders of Inhibikase Therapeutics?

Inhibikase Therapeutics's major institutional shareholders are HAMILTON LANE ADVISORS LLC. The top five shareholders own together 0% of the company's share outstanding.

How many Inhibikase Therapeutics shareholders are there?

As of Jun 2023, there are 1 institutional shareholders of Inhibikase Therapeutics.

What percentage of Inhibikase Therapeutics is owned by HAMILTON LANE ADVISORS LLC?

HAMILTON LANE ADVISORS LLC owns 0 shares of Inhibikase Therapeutics, representing 0% of the company's total shares outstanding, valued at $0 (as of Sep 2023).